Share This Author
TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1
It is collectively demonstrated that TXNIP stabilizes Redd1 protein induced by ATF4 in response to 2-DG, resulting in potentiation of mTOR suppression, the first study to identify TXNip as a novel member of the mTOR upstream that acts as a negative regulator in Response to stress signals.
C16‑ceramide and sphingosine 1‑phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.
Data suggest that CerS6 and SphK1 regulate mTOR signaling in breast cancer cell proliferation, and that mTOR activity can be regulated by the balance between S1P and C16‑ceramide, which is generated by CerS 6.
Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more…
Results: Among 364 patients(median age 51 years), TRCD was developed in 33 patients (9.3%) and was diagnosed within the first 6 months of trastuzumab (60.6%), which was significantly associated with prior anthracycline.
A pilot study of exercise intervention in patients with metastatic cancer: Feasibility, safety, and patient reported outcome.